Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

NCT05666804 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Polypoidal Choroidal Vasculopathy (PCV)

Interventions

DRUG: Brolucizumab 6mg
DRUG: Brolucizumab 6mg

Sponsor

Novartis Pharmaceuticals